Your selection

Research, Innovation / 01.11.2022
ASC Oncology proudly announces new partnership with Tamer Group

Dr. Christian Regenbrecht, CEO of ASC Oncology and Yasser Khattab, Sales Director of Tamer Group, sign the Memorandum of Understanding for a strategic partnership. (Photo: ASC Oncology)
Dr. Christian Regenbrecht, CEO of ASC Oncology and Yasser Khattab, Sales Director of Tamer Group, sign the Memorandum of Understanding for a strategic partnership. (Photo: ASC Oncology)

Cancer does not stop at borders - and neither does an approach to personalized cancer therapy developed in Berlin. Reverse Clinical Engineering® is now available to oncologists and cancer patients in Saudi Arabia, the Middle East, and North Africa.

Across borders, cancer is one of those diseases that is unpredictable, malignant and, despite high research efforts, not yet conquered. About 19.3 million people worldwide are diagnosed with cancer every year, and at the same time the prescribed chemotherapy fails in about half of all cancer patients. It is therefore essential to make advances in personalized cancer treatment available to doctors and cancer patients around the globe as quickly as possible and in a responsible manner.

Therefore, the Berlin-based biotech company ASC Oncology GmbH ("ASC Oncology") thinks beyond borders and is committed to the international use of Reverse Clinical Engineering® test procedure. The possibility that patients and oncologists know, based on scientific data, which drug is likely to work for an individual patient before a drug therapy is started should become a matter of course worldwide.

As an important next step in this journey, ASC Oncology today proudly announces its strategic partnership with Tamer Group. Through their century-long history, associated healthcare experience and the Tamer Group's large network in the Kingdom of Saudi Arabia, the Middle East and North Africa, the Reverse Clinical Engineering® testing procedure will thus become accessible to many patients as an important approach to personalized cancer therapy.

Tumor researcher Dr. Christian Regenbrecht, co-developer of the Reverse Clinical Engineering® procedure, emphasizes the benefits of the new partnership for cancer patients and treating physicians: "For three years, we have been using the testing procedure to support oncologists and patients in optimally individualising cancer treatment. With Reverse Clinical Engineering®, we test different drug treatment options before starting therapy and thus find the therapy option that is most likely to have an effect on the individual patient's tumor. Outside the patient's body and thus without side effects. This is a key step on the road to establishing personalized cancer therapy, which we are now taking together with the Tamer Group."

Reverse Clinical Engineering® enables oncologists to offer their patients effective therapy from the outset. Using a tissue sample of the patient's tumor taken during a biopsy or tumor surgery, 3D copies of the tumor, called organoids, are grown in the laboratory. In the next step, various cancer drugs are tested on these organoids to determine their effectiveness on the individual patient's tumor. In this way, on the one hand, a probably unsuccessful therapy can be prevented from unnecessarily burdening the cancer patient and, on the other hand, the chance of a therapeutic response can be significantly improved.

 

Who is ASC Oncology?

ASC Oncology was founded by nine leading scientists from the fields of expertise pathology, tumor biology, biochemistry, biotechnology and molecular biology in 2019 with the aim of addressing the most important challenge of modern oncology: Providing patients with the right therapy at the right time. In doing so, ASC Oncology scientists are stepping up to advance precision medicine internationally through the Reverse Clinical Engineering® procedure developed in Berlin to partner with oncologists to provide cancer patients with the best possible therapy from the start. Our goal is to provide better care to more patients than ever before in the history of oncology. ASC Oncology - Rethink Oncology.

www.asc-oncology.com

Overview News

News Buch Berlin

Change in the Supervisory Board of Eckert & Ziegler AG

Eckert Wagniskapital und Frühphasenfinanzierung GmbH has appointed radiation physicist Paola Eckert-Palvarini as its new representative on the Supervisory Board of Eckert & Ziegler AG

more ...

Changes in the Management Board of Eckert & Ziegler

The founder and CEO of Eckert & Ziegler AG (ISIN DE0005659700, SDAX), Dr. Andreas Eckert, today gave notice to the company that he intends to transfer from the Management to the Supervisory Board afte...

more ...

Understanding the transition to disease

As part of the IMMEDIATE project, a team led by ECRC researcher Friedemann Paul is investigating inflammatory precursors of diseases – and how nutrition and the gut microbiome influence the immune sys...

more ...

Events Buch Berlin

07.02.2023, 16:00
Literarisch-musikalischer Nachmittag über die Ukraine und ihre Menschen

mit der Autorin und Regisseurin Natalja Sharandak und der Sängerin und Liedermacherin Natalia Natalevych

more ...

13.02.2023, 09:00
GMP Biotech Winter School - Online

Good Manufacturing Practice (GMP) Basic Course Biotechnology (English) & ATMPs

more ...

14.02.2023, 10:00
Regionalwettbewerb „Jugend forscht“ auf dem Campus Berlin-Buch

"Mach Ideen groß“ – so lautet das diesjährige Motto des bundesweiten Wettbewerbs Jugend forscht. Auf dem Campus Berlin-Buch findet er in diesem Jahr in Präsenz statt.

more ...

This website is supported by: